OncoHost
OncoHost is a technology company transforming the approach to precision medicine for improved patient outcomes. Their mission is to translate the predictive power of proteomics into improved, truly personalized care that makes a real difference in the lives of patients worldwide.
Latest Content
Product News
OncoHost To Present Poster Demonstrating PROphet®’s Application in Multiple Cancer Indications at ASCO 2024
Plasma-based proteomic platform predicts clinical benefit from immune-checkpoint inhibitors in NSCLC, melanoma, and HPV-related cancers.
Industry Insight
Addressing One of the Most Common Dilemmas Faced by Oncologists
Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to learn about the challenges in non-small cell lung cancer treatment and how proteomics-based analysis could enable personalized cancer treatments.
Product News
OncoHost To Present Proteomics-Based Predictive Biomarker for Immune-Related Adverse Events in NSCLC Patients
Novel computational model accurately predicts significant irAEs in NSCLC patients based on proteomic profiling of one pre-treatment blood test.
Product News
OncoHost To Present PROphet® Biomarker Model That Accurately Predicts Clinical Benefit to ICI-Based Treatment
OncoHost has announced that it will give a poster presentation demonstrating the accuracy of its PROphet® biomarker model at the upcoming American Society of Clinical Oncology Annual Meeting, taking place June 2-6, 2023, in Chicago, Illinois.
Industry Insight
The Impact of Proteomics on Precision Oncology
To find out more about how proteomics is providing new insights into cancer dynamics and resistance mechanisms, we spoke to Dr. Ofer Sharon, CEO of OncoHost, a precision diagnostics company.
Product News
OncoHost To Present Proteomics-Based Biomarker Model for Clinical Benefit to Immunotherapy in NSCLC Patients at SITC 2022
OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitor in non-small cell lung cancer patients.
Product News
SomaLogic Announces License Agreement With OncoHost for the Development of Precision Cancer Diagnostics
SomaLogic has announced it has signed a licensing agreement with OncoHost.
Industry Insight
Driving Progress in Personalized Cancer Therapy
Personalized medicine has the potential to change the cancer patient's journey by predicting how they will respond to different treatments. Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to find out more!
Advertisement
